Polyphron Raises $20M Seed to Build Verification Substrate for Drug Discovery
AI drug-discovery startup Polyphron raised a $20M seed round from Gradient, Quiet Capital and Compound. Founded by Matthew Osman, the company builds a verification substrate using frontier models, with team members from Broad Institute, DeepMind, Ginkgo Bioworks and UC Berkeley.
2026-09-17 ~ 2026-09-17 · 4 related posts
- AI drug validation startup Polyphron raises $20M seed from Gradient, Quiet, Compound — darian314 · 2026-09-17
- Polyphron assembles all-star team from Broad, DeepMind, Ginkgo and Berkeley — darian314 · 2026-09-17
- Polyphron's all-star team draws from Broad Institute, DeepMind, Ginkgo and Berkeley AI — darian314 · 2026-09-17
- Polyphron raises backing to build the verification substrate for AI drug discovery — darian314 · 2026-09-17